AstraZeneca/ZSHP Acquisition Highlights Relypsa (RLYP) is Undervalued - Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
Relypsa (RLYP) Could Be Next High-Profile Takeout, Says Citi
November 6, 2015 10:09 AM ESTRelypsa (NASDAQ: RLYP) opened higher Friday after AstraZeneca (NYSE: AZN) announced a deal to acquire peer ZS Pharma (NASDAQ: ZSPH). The deal announcement stoked speculation Relypsa could be next a topic that was discussed in a research note by analysts at Citi.
Citi sees ZS Pharma's ZS-9 and Relypsa's Veltassa each... More



